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Abstract
The nuclear factor κB (NF-κB) is one of the most pivotal transcription factors in mam-
malian cells. In many pathologies NF-κB is activated abnormally. This contributes to 
the development of various disorders such as cancer, acute kidney injury, lung disease, 
chronic inflammatory diseases, cardiovascular disease, and diabetes. This book chapter 
focuses on how methylation of NF-κB regulates its target genes differentially. The knowl-
edge from this chapter will provide scientific strategies for innovative therapeutic inter-
vention of NF-κB in a wide range of diseases.
Keywords: arginine, epigenetic enzymes, gene regulation, lysine, methylation, NF-κb, 
transcription factor
1. Introduction
The nuclear factor κB (NF-κB) is one of the most pivotal transcription factors in mammalian 
cells. In many pathologies NF-κB is activated abnormally. This contributes to the development 
of various disorders such as cancer, acute kidney injury, lung disease, chronic inflammatory 
diseases, cardiovascular disease, and diabetes [1]. NF-κB family is comprised of five family 
members: p65 (RelA), RelB, c-Rel, p50/p105 (NF-kB1), and p52/p100 (NF-kB2). Among them, 
the Rel homology domain (RHD) at their N-termini is a commonly share feature (Figure 1). It 
is necessary for protein dimerization, the inhibition of NF-κB (IκB) interaction, nuclear target-
ing, and DNA binding [2]. Additionally, a carboxy-terminal transactivation domain (TAD) 
also exists in the Rel proteins, such as p65 (Figure 1), RelB, and c-Rel. Among the NF-κB 
dimers, the p65:p50 heterodimer is the prototype.
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The activity of NF-κB is frequently regulated by various modifications, namely, post-trans-
lational modifications (PTM). Among which, methylation is the newest type of modification 
that is discovered. The knowledge on NF-κB methylation is still scarce and not popularized 
among wide range of readers. Thus, in this chapter, we will focus on how methylation of 
NF-κB regulates its target genes differentially and provide perspectives and future directions 
in term of the research and application of NF-κB methylation. The knowledge from this chap-
ter will provide scientific strategies for innovative therapeutic intervention of NF-κB in a wide 
range of diseases.
2. NF-κB signaling pathways
The NF-κB signaling pathways play a very important role in signaling innate and adaptive 
immune responses and in many cellular processes. NF-κB signaling and subsequent target 
gene activation can be induced by a variety of factors including cytokines, stress, radiation, 
and also bacteria and viruses [3]. This signaling can be broken down into two signaling path-
ways: the canonical and non-canonical branches of the NF-κB pathway (Figure 2). In the 
canonical pathway, activity is regulated by interactions between IκB proteins and the p65:p50 
complex. IκB proteins hold NF-κB proteins in inactive conformations by binding in the cyto-
plasm and preventing nuclear localization. Extracellular signals including cytokines such as 
interleukin 1 β (IL-1β) and tumor necrosis factor α (TNFα), stress, free radicals, or radiation 
cause IκB kinase (IKK) activation. IKK is a complex that consists of the IKKα and IKKβ kinases 
and a third regulatory subunit known as NEMO/IKKγ [4, 5]. In the canonical pathway, IKKβ 
phosphorylates the N-terminal serine residues 32 and 36 of IκBα, resulting in its polyubiquiti-
nation and subsequent rapid proteasomal degradation [3]. This degradation allows the release 
of p65:p50 into the cytoplasm. The two-unit NF-κB complex then binds to the protein importin 
and translocates to the nucleus where it further binds to DNA and promotes increased expres-
sion of NF-κB target genes [6]. In the noncanonical pathway, the p100 and RelB proteins form 
an inactive dimer in the cytoplasm. Upon stimulation by a certain group of stimuli, such as 
B-cell activation factor (BAF) or CD40 ligand (CD40L), IKKα is subsequently activated through 
NF-κB-inducing kinase (NIK) mediation, leading to the ubiquitin/proteasomal processing of 
Figure 1. Diagram of the p65 subunit of NF-κB with methylation modifications. In the diagram, the arginine (R) 30 and 
lysine (K) 37, 218 and 221 are located at the Rel homology domain (RHD) (light gray), other 3 lysine sites K310, 314 and 
315 are located in the linker region (gray) between RHD and Transactivation domain (TA) (dark gray).
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p100 to p52. Once this processing has occurred, the RelB/p52 complex can translocate to the 
nucleus and bind to DNA to promote increased expression of NF-κB target genes [7].
3. The state of post-translational modifications (PTM) of NF-κB
Given the role of NF-ĸB in a wide range of important cellular and physiological processes, 
the potentially disastrous consequences of dysregulated NF-κB necessitates highly complex 
and finely regulated mechanisms for controlling NF-κB activity. NF-ĸB signaling can be influ-
enced at multiple levels, many of which converge on various components of the pathway 
including the IKK complex and the IĸB family of proteins [8]. For instance, the IKK complex 
remains one of the best-studied central regulators of NF-κB activation, and its phosphory-
lation of IκBα constitutes an essential event for subsequent signal transduction to both the 
canonical and non-canonical heterodimeric subunits of NF-κB [8, 9] as described above.
In addition to regulation by the IKK complex and the inhibitory IκB proteins, the NF-ĸB/Rel dimeric 
proteins are themselves subject to intricate regulation via a host of critical post-translational 
Figure 2. Two important NF-κB pathways. Left, in the canonical pathway, NF-κB subunit dimers are bound to inhibitory 
IκB proteins, which act to hold NF-κB complexes in an inactive state in the cytoplasm. Following stimulus of a receptor, 
the IκB kinase (IKK) complex becomes phosphorylated. IKK is made of two catalytically active kinases, IKKα and IKKβ, 
and the regulatory subunit IKKγ (NEMO). IKK then phosphorylates IκB proteins which are subsequently ubiquitinated 
and proteasomally degraded. This releases the bound subunits of NF-κB p65 and p50 into the cytoplasm. Following 
cytoplasmic release the subunits bind to importin and translocate to the nucleus where they can bind to the promoter 
and trigger the transcriptional activation of NF-κB target genes. Right, in the noncanonical pathway, the p100/RelB 
dimer remains in an inactive state until stimulated by a signaling cascade triggered by factors including CD40L or 
BAFF. Following stimulus and subsequent phosphorylation of IKKα by NIK, IKKα phosphorylates p100 associated with 
RelB, which leads to its ubiquitination and proteasomal processing to p52. The complexed p52/RelB can then translocate 
to the nucleus and bind to the target gene promoters and further activate the transcription of the NF-κB target genes.
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modification (PTM) events [10–12]. PTMs on p65, the prototypical subunit of NF-κB, include 
[13, 14], acetylation [15–19], methylation [20–23], ubiquitination [24], nitrosylation [25], and 
sumoylation [26]. The consequences of these regulatory modifications are context dependent, 
and vary based on the nature and abundance of the NF-κB pathway stimulators [11, 22]. 
Moreover, the sites and/or crosstalk between modifications [16, 27] can yield different out-
comes with even the same modifications yielding quite distinct physiological effects [28–31]. 
Eventually, these PTMs work to dictate the duration and strength of activation and, accord-
ingly, the degree of transcriptional output [10, 32]. Moreover, some of these modifications 
serve as important means for crosstalk with other signaling pathways [33].
Our laboratory is one of the first few groups to discover that p65 can be methylated on lysine 
residues upon cytokine stimulation [20]. Subsequently, we pioneered the identification of 
arginine 30 (R30) methylation of p65 [22]. Below, we will thoroughly discuss the impact of 
these methylation sites on NF-κB-mediated differential gene regulation.
4. Methylation of the p65 subunit of NF-κB
4.1. Lysine methylation of p65
To date, a total of six lysine methylation sites have been reported: K37, 218, 221, 310, 314, and 
315 [18, 20]. By using a novel genetic approach, our lab identified that p65 can be methyl-
ated by a lysine methylase, the nuclear receptor-binding SET domain-containing protein 1 
(NSD1), and demethylated by a lysine demethylase, the F-box and leucine-rich repeat protein 
11 (FBXL11) [20]. This reversible lysine methylation of p65 is targeted at K218/K221 sites and 
affects NF-κB activity. K218/K221 methylation induces over 80% p65-dependent gene expres-
sion in mouse embryonic fibroblast cells (MEFs). The observation indicates that PTMs play an 
important role in fine-tuning the regulation of NF-κB [20].
Zhang et al. provided strong evidence regarding the function of p65 methylation by reporting 
that in response to TNFα, plant homeodomain finger protein 20 (PHF20) promotes NF-κB 
transcriptional activity by interacting with methylated p65 at K218/221. The methylation of 
p65 blocks recruitment of PP2A to p65, thereby leading to the persistent phosphorylation of 
p65 [34]. By using the immunohistochemistry (IHC) staining method, the authors showed 
that PHF20 and phosphorylated p65 are localized in the nucleus in glioma tissue specimens. 
The PHF20 expression levels are also tightly correlated with the clinical tumor grade after 
univariate analysis with a P value of 0.0018 (P < 0.05 is considered to be significant). These 
findings highlight the interrelated connections between overexpressed PHF20, methylation, 
and phosphorylation of p65 in human malignant gliomas [34].
In addition to our discovery of the methylation of K218/221, Ea et al. revealed that p65 
is monomethylated by histone methyltransferase, the Set domain-containing protein 
9 (Set9) at K37 in response to both IL-1β and TNFα treatment. The authors showed that 
TNFα induced p65 monomethylation is essential for the expression of NF-κB regulated 
genes. Methylated p65 stays in the nucleus, and Set9 might regulate its nuclear function. 
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Moreover, monomethylation of p65 increases the NF-κB DNA binding ability and recruit-
ment to the promoter of NF-κB target genes [18]. Interestingly, Yang et al. described that 
Set9 may also monomethylate p65 at K314 and K315 in addition to K37, and negatively 
regulate p65. The authors suggested that methylation of K314/315 inhibits the transcrip-
tional activity of NF-κB through proteasome-mediated degradation, and it downregulates 
NF-κB target gene expression [19], a phenomenon quite different from that of K37 methyla-
tion. Collectively, this evidence suggests the complexity of p65 methylation, and indicates 
that the same enzyme, such as SET9, may have different functions depending on the lysine 
residues it modifies. There is also a possibility that K37 modification occurs before K314/
K315 methylation. It is likely that K37 methylation is required for gene activation, while 
K314/315 methylation is required for the termination of NF-κB activity [18].
Besides the methylated lysine residues on p65 discussed above, another SET family mem-
ber SETD6, was also reported to monomethylate p65 at K310 under basal condition. Levy 
and colleagues observed that under the unstimulated condition, a proportion of p65 can be 
monomethylated by SETD6. This methylation event negatively regulates NF-κB target gene 
expression, including those involved in inflammatory response. The phenotype was proven 
in various cell lines, such as bone osteosarcoma U2OS, peripheral blood THP-1, and bone 
marrow-derived macrophages (BMDM), and therefore represents diverse disease models. 
Interestingly, Levy et al. found that K310 monomethylation-mediated NF-κB inhibition is due 
to the involvement of another protein, the G9A-like protein (GLP). By binding to monometh-
ylated K310, GLP enriches histone H3K9 dimethylation on the p65 target gene promoters, 
resulting in gene suppression. This SETD6-initiated lysine-methylation repressive pathway 
can be terminated by p65 phosphorylation at serine 311 (S311) and by the atypical protein 
kinase PKC-ζ [23]. This study presents a delicate example of how methylation and phos-
phorylation on p65 may regulate each other and be an integral part of a more sophisticated 
regulatory system of NF-κB.
An overlook of the biological roles of p65 lysine methylation and their modifying enzymes is 
shown in Table 1. It is evident that under various experimental conditions, p65 lysine meth-
ylation may affect NF-κB nucleus localization, transcriptional activity, and NF-κB target gene 
expression.
4.2. Arginine methylation of p65
Distinct from the methylation of lysine residues, our lab used Mass Spectrometry to discover 
that p65 can also be symmetrically methylated at arginine 30 residue (R30) [20, 22]. This 
important modification is carried out by the protein arginine methyltransferase 5 (PRMT5), 
an enzyme that belongs to the PRMT superfamily, contains 637 amino acids, and catalyzes the 
formation of symmetrically dimethylated arginine.
We reported that PRMT5 catalyzed p65 dimethylation upon IL-1β treatment. R30 to A mutant 
(R30A) of p65 decreased NF-κB activity and led to the downregulation of a subgroup of 
NF-κB inducible genes; among these are cytokine and chemokine genes. Conditional media 
from cells expressing the R30A mutant of p65 had much less NF-kB-inducing activity than its 
wild-type cohort. Additionally, through In Silico prediction we proposed that dimethylation 
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of R30 may mediate van der Waals contacts and stabilize domain interactions. The key residues 
involved are aspartic acid (D) 277, glutamic acid (E) 279, and threonine (T) 191. Since phenyl-
alanine (F) 184 positions closely to R30 and T191, R30 is sandwiched between F184/T191 on 
one side and D277/E279 on the other. This evidence affirms the importance of R30 methyla-
tion in increasing the ability of p65 to bind to DNA, resulting in the changes in its target gene 
expression [22].
Further demonstrating the complexity of R30 methylation, Reintjes et al. reported that PRMT1, 
another member of the PRMT superfamily, may asymmetrically methylate p65 at the same 
R30 that is symmetrically methylated by PRMT5 [35]. The information of R30 methylation by 
both PRMT5 and 1 is also included in Table 1. Different from PRMT5, PRMT1 is an enzyme 
containing 361 amino acids which catalyzes the formation of monomethyl-arginine and 
asymmetric dimethyl-arginine [36]. Reintjes and colleagues proposed an interesting model 
suggesting that symmetric dimethylation of R30 by PRMT5 seems to be induced at early time 
points, however, asymmetric dimethylation of R30 by PRMT1 is enriched at later time points. 
This idea presents an overall picture of the “meticulously calculated” regulation of NF-κB 
signaling, through symmetric and/or asymmetric R30 dimethylation that occurs at differ-
ent stages of NF-κB responses. This model represents a specific on/off switch mechanism for 
adjusting cytokine-induced NF-κB responses [35].
Type of methylation Site 
modified
Enzymes Biological function Reference
Monomethylation K37 SET9 Stabilizes nuclear localization and 
enhances p65 binding ability
[18]
Monomethylation K218 NSD1/FBXL11 Promotes NF-κB transcriptional 
activity and maintains p65 
phosphorylation on S536
[20, 34]
Dimethylation K221 NSD1/ FBXL11 Promotes NF-κB transcriptional 
activity and maintains p65 
phosphorylation on S536
[20, 34]
Monomethylation K310 SETD6 Decreases NF-κB target gene 
expression
[23]
Monomethylation K314 SET9 Decreases NF-κB activity and target 
gene expression
[19]
Monomethylation K315 SET9 Decreases NF-κB activity and target 
gene expression
[19]
Symmetric dimethylation R30 PRMT5 Enhances NF-κB DNA binding 
and transcriptional activities, 
and increases NF-κB target gene 
expression
[22, 35]
Asymmetric dimethylation R30 PRMT1 Reduces NF-κB DNA binding 
ability and decreases NF-κB target 
genes expression
[22, 35]
Table 1. Types of NF-κB methylation and its biological roles.
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4.3. Differential gene regulation by lysine and arginine methylation
As we mentioned earlier, a total of six lysine methylation sites can be methylated by different 
histone lysine methyltransferases in response to activating signals. Among them, K37, K218, 
and K221 are located in the RHD domain, while K310, K314, and K315 are in the linker region 
between RHD and the transactivation domain (TA) [36] (Figure 1). Using site mutagenesis, we 
generated the K218/221Q double mutant (DKQ) or the K37Q single mutant of p65. We found 
that in response to cytokines, such as IL-1β treatment, ~350 genes were rapidly induced within 
5 min after treatment, while an additional ~300 genes were significantly upregulated 30 min 
later. Additionally, 1500 genes were further induced between the time points of 1 and 24 h. We 
revealed that early growth response protein 1 (EGR1) was upregulated within 30 min and then 
began to decrease after 2 h. While C-X-C motif chemokine 10 (CXCL10, also known as IP10), and 
Interleukin 8 (IL-8) were upregulated after 1 h or longer treatment. However, their expression 
is much more stable than the EGR gene [21]. To further explore the different effects of DKQ 
and K37Q on gene expression, we conducted an Illumina array analysis, observing that DKQ 
is responsible for ~50%, while K37Q is only responsible for ~25% of NF-κB target gene regu-
lation. Among these genes, some were exclusively regulated by either DKQ or K37Q, while 
others were commonly regulated by both DKQ and K37Q. This is a very interesting phenom-
enon. Our work showed that a very tiny difference in NF-κB methylation, such as methylation 
on different lysine residues, could lead to dramatically different gene induction patterns. By 
using ChIP-seq and bioinformatics approaches, we further uncovered that NF-κB target genes 
can be classified into multiple subgroups based on the effects of DKQ or K37Q (up- or down-
regulation, or lysine site sensitivity) [21]. This data offers a valuable picture of the dynamic 
complexity of gene regulation by methylation of NF-κB on different lysine residues.
To further determine the difference between K and R methylation of p65 on NF-κB regulation, 
we conducted similar experiments as described above [21]. R30A and DKA (K218/221 K-A) 
mutants were generated in HEK293 cells. Illumina microarray experiments were carried out 
to analyze the gene populations affected by these mutations. We found that ~75% of NF-κB 
target genes were down-regulated by twofold or more by the R30A mutation, while signifi-
cantly fewer (~48%) genes were downregulated by the DKA mutation. This data suggests 
that R30 methylation is in charge of most NF-κB target gene expression, while K218/221 
methylation controls a much smaller population of the genes. Not surprisingly, Ingenuity 
Pathway Analysis (Figure 3) revealed that R30A and DKA control different functional net-
works. For instance, the top network for R30A is regarding the functions of Cellular Movement, 
Hematological System Development and Function, Immune Cell Trafficking, while the top network 
for DKA is related to Cell-mediated Immune Response, Cellular Development, Cellular Function 
and Maintenance, affirming the quite distinct cellular functions of R30 and K218/221 methyla-
tion. Figure 4 illustrates a representative network from either R30A or DKA regulated genes. 
Importantly, the NF-κB complex is identified as a critical node in both networks. Two typical 
NF-κB target genes, IL8 (CXCL8) and IP10 (CXCL10), are also shown as important compo-
nents in both networks.
Collectively, the evidence described above proves that methylation on different lysine resi-
dues or on different types of amino acids (lysine vs. arginine) on the p65 subunit of NF-κB, 
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dictates differential gene regulation, leading to complex and distinct outcomes. The work on 
methylation of NF-κB has offered a unique angle for understanding the mechanisms under-
lying the extreme plasticity of the biological responses led by the finely tuned regulation of 
NF-κB. The knowledge gained by this study will enable us to better understand why NF-κB 
is dysregulated in a variety of disease states, thus providing critical guidance to the design of 
disease-specific therapeutics.
Figure 3. Top networks that are affected by either R30A or DKA mutations. Ingenuity pathway analysis (IPA), showing 
top five different functional networks that are associated with R30A or DKA mutation.
Figure 4. Example networks of R30A and DKA mutations, with NF-κB as a master node. Left panel, R30A mutation 
affects NF-κB orchestrated network. Right panel, DKA mutation interferes with NF-κB signaling. However, these two 
networks show quite distinct topographies and interactions with other signaling components. Note: Both IL8 and IP10 
are within the networks.
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5. Histone methylases as potential therapeutic targets in cancer
Due to the important role of NF-κB methylation in differential gene regulation, it is logical 
to recognize the essential roles of the enzymes that catalyze these methylation modifications. 
These enzymes are frequently histone methylases, and there are quite a few examples. Since 
the role of histone methylases in cancer has been well reviewed by Albert and Helin [37], 
below, we will only focus on PRMT5.
PRMT5 has been increasingly recognized as an important tumor promoter. We and others have 
observed elevated PRMT5 expression in cancers of the colon, pancreas, ovary, kidney, lung, 
bladder, liver, breast, prostate, cervix, and skin. This suggests that high levels of this enzyme 
may promote tumorigenesis, at least in part by facilitating NF-κB-induced gene expression [22, 
38]. For instance, by conducting colorectal cancer (CRC) tissue microarray (TMA), we found 
that PRMT5 is overexpressed in polyps, advanced stages of colorectal cancer, and in the meta-
static stage [39]. Similarly, PRMT5 is also overexpressed in various stages of pancreatic cancer, 
especially in the metastatic stage [39]. We proved that overexpression of PRMT5 promotes CRC 
HT29 cell and pancreatic cancer PANC1 cell proliferation, anchorage-independent growth, and 
cell migration ability. Knockdown of PRMT5 by shRNA showed the opposite effect, confirming 
PRMT5 functions as a tumor promoter in these cancers [39].
Additionally, overexpression of PRMT5 has been shown to be associated with poor epithelial 
ovarian cancer prognosis [40]. In a clinical study with 150 ovarian cancer patient samples, the 
overexpression of PRMT5 is found to be highly correlated with the Federation of Gynecology 
and Obstetrics (FIGO) advanced stage, which includes poor cell differentiation, high prolif-
eration activity, and lymph node involvement. The overall survival rate of patients with low 
PRMT5 expression is 90%. In contrast, only 30% of patients with high PRMT5 expression 
survived. The progression-free survival rate is 50% for patients with low PRMT5 expression, 
but in those with high PRMT5 expression the rate is only 10% [40].
Moreover, Kumar and colleagues showed that the expression level of PRMT5 is inversely cor-
related with oropharyngeal squamous cell carcinoma (OPSCC) patient outcome. For instance, 
high PRMT5 expression correlated with low overall survival and had over 1.7 times higher 
death risk than the patient who has low PRMT5 expression [41]. Together, these studies have 
identified PRMT5 as a promising therapeutic target in cancers.
To date, multiple efforts have been made to develop the small molecule inhibitors of PRMT5. 
For instance, EPZ015666 was reported [39, 42] to inhibit PRMT5 methyltransferase activity 
in panels of mantle cell lymphoma (MCL) cell lines (Maver-1, Mino, Granta-519, Jeko-1and 
Z-138). It also significantly inhibits tumor growth in Z-138 and Maver-1 MCL xenograft 
mouse model as compare with vehicle control.
Recently, by adapting the AlphaLISA technique into a sensitive high throughput screening 
platform, our lab identified PR5-LL-CM01 as a potent PRMT5 small molecule inhibitor. PR5-
LL-CM01 showed greater potency than EPZ015666 in both PDAC and CRC model [39].
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These examples highlight the great potential of using histone methylases, such as PRMT5, as 
novel therapeutic targets in cancer.
Likewise, other histone methylases (Table 1) that methylate NF-κB may also play critical 
roles in the development and progression of cancer and other hyper NF-κB driven diseases. 
Therefore, they constitute a group of highly promising future therapeutic targets for these 
pathological conditions.
6. Conclusion, perspective, and future directions
The implications of methylation of NF-κB are multi-fold and far reaching. Methylation pro-
vides a snapshot of the complexity underlying the regulation of this important transcription 
factor. Even with the studies done to date, researchers have just begun to understand the 
crosstalk between these different PTMs and their implications in normal cellular function and 
disease. Two interesting questions remain. First, how does methylation of these residues on 
the same subunit affect NF-κB function? Second, can we reconcile the effects of other kinds of 
PTMs coupled with methylation both in normal and diseases states? A deeper understanding 
of these aspects will shed important light on the overall strategies for the development of new 
therapeutic approaches to treat the affected diseases.
Cancer is one of the leading causes of morbidity and mortality worldwide. Methylation of 
NF-κB as described in this review highlights its significance in cancers and other inflamma-
tory diseases. Over the past decade, several transformative discoveries in epigenetics have led 
to the development of novel therapies that target epigenetic enzymes. However, the inquiries 
into acetylation and methylation modifications of lysines and arginines have been mainly 
focused on histone proteins. Important research identifying methylation residues on impor-
tant non-histone proteins like NF-κB may be crucial to developing therapeutic interventions 
that target these modifications. For instance, the PRMT5 inhibitor identified in our laboratory 
has paved the way for future drug development to treat cancers and other disease with hyper 
PRMT5-driven NF-κB activity [22, 39]. In addition to PRMT5, other histone methylases, such 
as NSD1, have been reported by us and others as a significant player in cancer development 
[20, 43–45]. Although researchers have been trying to develop a small NSD1 inhibitor for 
cancer treatment, no NSD1 specific inhibitor has yet been reported due to the large size of 
NSD1 enzyme and the lack of sufficiently sensitive assay development. Future effort on this 
front and other histone methylases are equally as important in developing new medicines 
that target PRMT5.
Additionally, as mentioned in the Introduction, the prototypical NF-κB is comprised of a 
heterodimer of p65 and p50 subunits. Though multiple sites of methylation have been dis-
covered on the p65 subunit of NF-κB, the potential methylation of the p50 subunit is quite 
understudied. With recent advances in proteomics and prediction software, novel methyla-
tion site(s) on p50 could arise in the near future. The study on p50 methylation could provide 
more a complete picture in terms of NF-κB regulation, and may possibly lead to novel discov-
eries regarding the methylation-mediated regulation of this subunit as well.
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Since NF-κB is an important transcription factor that also plays a fundamental role in normal 
cells, one must consider important factors such as specificity of inhibiting modification only in 
cancer cells but not in normal cells. Multi-targeted approaches that simultaneously cripple sev-
eral signaling pathways in cancer cells would be ideal, and a better understanding of the crosstalk 
between these pathways will advance the drug development process. In the future, a combina-
tion of advanced animal models, Cas9/CRISPR system, and more sophisticated bioinformatics 
approaches will serve as invaluable tools to study the implications of methylation on NF-κB and 
its interactions with other critical cellular factors that are important in the disease context. This 
will help to expedite the development of therapeutic tools to combat these deadly diseases.
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Abbreviation
BAF  B-cell activation factor
BMDM  bone marrow-derived macrophages
CD40L  CD40 ligand
ChIP-seq chromatin immunoprecipitation (ChIP) with DNA sequencing
CRC  colorectal cancer
CXCL10  C-X-C motif chemokine 10 (also known as IP10)
EGR1  early growth response protein
FBXL11  F-box and leucine-rich repeat protein 11
FIGO  Federation of Gynecology and Obstetrics
GLP  G9A-like protein
IHC  immunohistochemistry
IKK  IκB kinase
IL-1β  interleukin 1 β
IL-8  Interleukin 8
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MCL  mantle cell lymphoma
MEFs  mouse embryonic fibroblast cells
NF-κB  nuclear factor κB
NIK  NF-κB-inducing kinase
NSD1  nuclear receptor-binding SET domain-containing protein 1
OPSCC  oropharyngeal squamous cell carcinoma
PHF20  plant homeodomain finger protein 20
PKC-ζ  Protein kinase C zeta
PRMT1  protein arginine methyltransferase 1
PRMT5  protein arginine methyltransferase 5
PTM  post-translational modifications
RHD  Rel homology domain
Set9  Set domain-containing protein 9
TAD  transactivation domain
TMA  tissue microarray
TNFα  tumor necrosis factor α
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